cirrhotic


Also found in: Thesaurus, Medical, Encyclopedia.
Related to cirrhotic: Hepatic cirrhosis

cir·rho·sis

 (sĭ-rō′sĭs)
n.
1. Any of various chronic diseases of the liver characterized by the replacement of normal tissue with fibrous tissue and the loss of functional liver cells, resulting from a variety of causes that include chronic alcoholism and certain diseases and infections, especially hepatitis C.
2. Chronic interstitial inflammation of any tissue or organ. No longer in clinical use.

[New Latin : Greek kirros, tawny (from the color of the diseased liver) + -osis.]

cir·rhot′ic (-rŏt′ĭk) adj.
Translations

cirrhotic

adj & n cirrótico -ca mf
References in periodicals archive ?
In cirrhotic patients due to fibrosis and nodule formation there is obstruction to the portal venous flow.
Wasim Jafri remarked that HBV positive patients can be a donor but cirrhotic cannot be donors for liver transplant.
Besides the hepatorenal syndrome this has led to the recognition of new clinical entities, such as cirrhotic cardiomyopathy and the hepatopulmonary syndrome.
It is known the high risk of duodenal ulcer bleeding in cirrhotic patients; therefore, we suggest that the prudent physician should always test for the presence of H.
However, there is also some evidence to support its use in cirrhotic populations.
The study demonstrated that OCR-002 reduced time to improvement in cirrhotic patients hospitalized with HE and elevated baseline ammonia, compared to placebo + standard of care (SOC) (p=0.
However, in cirrhotic patients, hyponatremia is labeled when the concentration of serum sodium is <130 meq/l).
Materials and Methods: Four variables (platelet count, portal vein diameter, splenic diameter, and ratio of platelet count to splenic diameter PC/SD] ratio) were studied in 150 cirrhotic patients.
Among these categories patients were divided as Non cirrhotic and Cirrhotic furthermore,cirrhotic involves Compensated CLD and Decompensated CLD.
Discussion: Morbidity, mortality and blood loss were comparatively higher in cirrhotic patients.
Regimens containing sofosbuvir and velpatasvir were most effective for treating both cirrhotic and non-cirrhotic genotype 3 hepatitis C virus infection, according to a meta-analysis.
1) Being infected by genotypes 1a or 3, cirrhotic, and previously exposed to interferon-containing regimens are predictors of non-response.